Scailyte develops artificial intelligence technology for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases by uncovering human's hidden "single-cell"? secrets. Our AI-based software ScaiVision offers best-in-class performance for supervised pattern recognition analysis of single-cell data. The performance and clinically-relevant application of the deep learning algorithm have been demonstrated in a scientific publication by our co-founder Prof. Claassen (ETH Zurich). ScaiVision will allow our customers to reduce data analysis time and costs, while increasing groundbreaking insights.

Moreover, we are also providing biomarker discovery services leveraging our expertise in single-cell technologies and our AI-based data analytics solutions. We support pharmaceutical companies during the drug discovery & development process by introducing and implementing single-cell approaches for the discovery of novel disease mechanisms, as well as the discovery of biomarkers for drug efficacy, toxicity, and patient stratification. Our AI platform, ScaiVision, combines features to integrate different datasets, is indication- and cell-type agnostic and uses data augmentation and a cluster-free approach to extract relevant information while retaining single-cell resolution. These features result in very high discovery success rates from a limited number of samples, with actionable insights for the basis of assay development.